InvestLog
HLN Haleon plc logo

HLN Haleon plc

Healthcare
$9.29-0.32%ClosedMarket Cap: $41.25B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

31.80

PEG

0.40

P/B

1.90

P/S

3.70

EV/EBITDA

18.19

DCF Value

$18.96

FCF Yield

3.1%

Div Yield

2.1%

Margins & Returns

Gross Margin

61.5%

Operating Margin

18.8%

Net Margin

12.6%

ROE

6.4%

ROA

3.2%

ROIC

4.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 null$5.52B$855.7M$—
FY null$10.79B$1.63B$—
Q2 null$5.48B$806.0M$—
Q1 null$2.74B$403.0M$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$10.20

Target (Median)

$10.20

Target Range

$10.20 - $10.20

2 Strong Buy1 Buy2 Hold0 Sell0 Strong Sell
BarclaysOverweight
2026-01-23
BarclaysEqual Weight
2025-09-16

Company Info

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

GB

Exchange

—

Beta

0.25

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.

Peers

A logoAALC logoALCBDX logoBDXCAH logoCAHHUM logoHUMINSM logoINSMIQV logoIQVRMD logoRMDTAK logoTAKZTS logoZTS